SLC5A2 and Hypoglycemia: Key findings highlighted that combination therapies involving SGLT2 inhibitors and DPP-4 inhibitors often resulted in greater reductions in HbA1c and weight loss compared to other treatments, while insulin was more effective in lowering glucose but came with a higher risk of hypoglycemia and weight gain.